Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl in prostate cancer

An Italian multicentric trial

F. Boccardo, A. Decensi, D. Guarneri, A. Rubagotti, G. Martorana, C. Giberti, G. B. Cerruti, F. Tani, A. Zanollo, T. Germinale, C. Borzone, F. Perri, E. Usai, L. Santi, L. Guiliani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treawted with the long-acting formulation of D-TRP-6 LH-RH (Decapeptyl) for up to 39 months. Of 88 patients evaluable for response, about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms were obtained. Five patients claimed a mild increase in bone pain and one patient a slight worsening of dysuria following the first injection. Median progression-free survival was 13.1 and 16.4 months in patients with stage D2 and D1, respectively. Median survival in stage D2 patients was 27.6 months. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.

Original languageEnglish
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue numberSUPPL. 2
Publication statusPublished - 1988

Fingerprint

Triptorelin Pamoate
Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Dysuria
Bone and Bones
Pain
Disease-Free Survival
Carcinoma
Injections
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Boccardo, F., Decensi, A., Guarneri, D., Rubagotti, A., Martorana, G., Giberti, C., ... Guiliani, L. (1988). Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl in prostate cancer: An Italian multicentric trial. American Journal of Clinical Oncology: Cancer Clinical Trials, 11(SUPPL. 2).

Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl in prostate cancer : An Italian multicentric trial. / Boccardo, F.; Decensi, A.; Guarneri, D.; Rubagotti, A.; Martorana, G.; Giberti, C.; Cerruti, G. B.; Tani, F.; Zanollo, A.; Germinale, T.; Borzone, C.; Perri, F.; Usai, E.; Santi, L.; Guiliani, L.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 11, No. SUPPL. 2, 1988.

Research output: Contribution to journalArticle

Boccardo, F, Decensi, A, Guarneri, D, Rubagotti, A, Martorana, G, Giberti, C, Cerruti, GB, Tani, F, Zanollo, A, Germinale, T, Borzone, C, Perri, F, Usai, E, Santi, L & Guiliani, L 1988, 'Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl in prostate cancer: An Italian multicentric trial', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 11, no. SUPPL. 2.
Boccardo, F. ; Decensi, A. ; Guarneri, D. ; Rubagotti, A. ; Martorana, G. ; Giberti, C. ; Cerruti, G. B. ; Tani, F. ; Zanollo, A. ; Germinale, T. ; Borzone, C. ; Perri, F. ; Usai, E. ; Santi, L. ; Guiliani, L. / Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl in prostate cancer : An Italian multicentric trial. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1988 ; Vol. 11, No. SUPPL. 2.
@article{2761e1dab5b94a658c7f9ca0d87694b1,
title = "Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl in prostate cancer: An Italian multicentric trial",
abstract = "Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treawted with the long-acting formulation of D-TRP-6 LH-RH (Decapeptyl) for up to 39 months. Of 88 patients evaluable for response, about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms were obtained. Five patients claimed a mild increase in bone pain and one patient a slight worsening of dysuria following the first injection. Median progression-free survival was 13.1 and 16.4 months in patients with stage D2 and D1, respectively. Median survival in stage D2 patients was 27.6 months. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.",
author = "F. Boccardo and A. Decensi and D. Guarneri and A. Rubagotti and G. Martorana and C. Giberti and Cerruti, {G. B.} and F. Tani and A. Zanollo and T. Germinale and C. Borzone and F. Perri and E. Usai and L. Santi and L. Guiliani",
year = "1988",
language = "English",
volume = "11",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl in prostate cancer

T2 - An Italian multicentric trial

AU - Boccardo, F.

AU - Decensi, A.

AU - Guarneri, D.

AU - Rubagotti, A.

AU - Martorana, G.

AU - Giberti, C.

AU - Cerruti, G. B.

AU - Tani, F.

AU - Zanollo, A.

AU - Germinale, T.

AU - Borzone, C.

AU - Perri, F.

AU - Usai, E.

AU - Santi, L.

AU - Guiliani, L.

PY - 1988

Y1 - 1988

N2 - Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treawted with the long-acting formulation of D-TRP-6 LH-RH (Decapeptyl) for up to 39 months. Of 88 patients evaluable for response, about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms were obtained. Five patients claimed a mild increase in bone pain and one patient a slight worsening of dysuria following the first injection. Median progression-free survival was 13.1 and 16.4 months in patients with stage D2 and D1, respectively. Median survival in stage D2 patients was 27.6 months. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.

AB - Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treawted with the long-acting formulation of D-TRP-6 LH-RH (Decapeptyl) for up to 39 months. Of 88 patients evaluable for response, about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms were obtained. Five patients claimed a mild increase in bone pain and one patient a slight worsening of dysuria following the first injection. Median progression-free survival was 13.1 and 16.4 months in patients with stage D2 and D1, respectively. Median survival in stage D2 patients was 27.6 months. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0024217254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024217254&partnerID=8YFLogxK

M3 - Article

VL - 11

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - SUPPL. 2

ER -